IGHV3OR16-8

Across TCGA pan-cancer cohorts, IGHV3OR16-8 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHV3OR16-8 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IGHV3OR16-8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3OR16-8 expression acts as an unfavorable survival marker.

UCEC and LUAD are the cancer types where IGHV3OR16-8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IGHV3OR16-8–UCEC (OS)

Open the UCEC breakdown →